Lung Cancer
Volume 62, Issue 1 , Pages 92-98 , October 2008

Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: Analysis of CALGB phase III trial 9235

  • Jeffrey A. Bogart

      Affiliations

    • SUNY Upstate Medical University, Radiation Oncology Department, 750 E. Adams Street, Syracuse, NY 13210, United States2
    • For Cancer and Leukemia Group B (Chicago, IL) and Quality Assurance Review Center (Providence, RI).
    • Corresponding Author InformationCorresponding author. Tel.: +1 315 464 5276; fax: +1 315 464 5939.
    • ,
  • Dorothy Watson

      Affiliations

    • CALGB Statistical Center, Duke University Medical Center, Durham, NC, United States3
    • For Cancer and Leukemia Group B (Chicago, IL) and Quality Assurance Review Center (Providence, RI).
    • ,
  • Edward F. McClay

      Affiliations

    • University of California at San Diego, San Diego, CA, United States4
    • For Cancer and Leukemia Group B (Chicago, IL) and Quality Assurance Review Center (Providence, RI).
    • ,
  • Lisa Evans

      Affiliations

    • Southeast Cancer Control Consortium Inc., CCOP, Goldsboro, NC, United States5
    • For Cancer and Leukemia Group B (Chicago, IL) and Quality Assurance Review Center (Providence, RI).
    • ,
  • James E. Herndon

      Affiliations

    • CALGB Statistical Center, Duke University Medical Center, Durham, NC, United States3
    • For Cancer and Leukemia Group B (Chicago, IL) and Quality Assurance Review Center (Providence, RI).
    • ,
  • Frances Laurie

      Affiliations

    • Quality Assurance Review Center, Independent Laboratories, Providence, RI, United States
    • For Cancer and Leukemia Group B (Chicago, IL) and Quality Assurance Review Center (Providence, RI).
    • ,
  • Stephen L. Seagren

      Affiliations

    • University of California at San Diego, San Diego, CA, United States4
    • For Cancer and Leukemia Group B (Chicago, IL) and Quality Assurance Review Center (Providence, RI).
    • ,
  • T.J. Fitzgerald

      Affiliations

    • Quality Assurance Review Center, Independent Laboratories, Providence, RI, United States
    • For Cancer and Leukemia Group B (Chicago, IL) and Quality Assurance Review Center (Providence, RI).
    • ,
  • Everett Vokes

      Affiliations

    • University of Chicago, Chicago, IL, United States6
    • For Cancer and Leukemia Group B (Chicago, IL) and Quality Assurance Review Center (Providence, RI).
    • ,
  • Mark R. Green

      Affiliations

    • Southeast Cancer Control Consortium Inc., CCOP, Goldsboro, NC, United States5
    • For Cancer and Leukemia Group B (Chicago, IL) and Quality Assurance Review Center (Providence, RI).

Received 19 October 2007 ,Revised 20 January 2008 ,Accepted 9 February 2008.

References 

  1. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–1624
  2. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10:890–895
  3. Movsas B, Moughan J, Komaki R, Choy H, Byhardt R, Langer C, et al. Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol. 2003;21:4553–4559
  4. Langer C, Moughan J, Movsas B, Komaki R, Ettinger D, Owen J, et al. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?. Lung Cancer. 2005;48:93–102
  5. Jeremic B. Patterns of care survey (PCS) in chemotherapy (CHT) in nonmetastatic lung cancer. Lung Cancer. 2005;48:103–105
  6. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20:3054–3060
  7. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RT, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–271
  8. Videtic G, Fung K, Tomiak A, Stitt LW, Dar AR, Truong PT, et al. Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. Lung Cancer. 2001;33:249–258
  9. McClay EF, Bogart J, Herndon JE, Watson D, Evans L, Seagren S, et al. A Phase III trial evaluating the combination of cisplatin, etoposide, radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). Am J Clin Oncol. 2005;28:81–90
  10. Pajak TF, Laramore GE, Marcial VA, Fazekas JT, Cooper J, Rubin P, et al. Elapsed treatment days—a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys. 1991;20:13–20
  11. Koukourakis M, Hlouveratsis G, Kosma L, Skarlatos J, Damilakis J, Giatromanolaki A, et al. The impact of overall treatment time on the results of radiotherapy for nonsmall cell carcinoma. Int J Radiat Oncol Biol Phys. 1996;34:315–322
  12. Cox JD, Pajak TF, Marcial VA, Coia L, Mohiuddin N, Fu KK, et al. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory/digestive tracts: New evidence for accelerated proliferation from Radiation Therapy Oncology Group protocol 8313. Cancer. 1992;69:2744–2748
  13. Jeremic B, Shibamoto Y, Milicic B, Dagovic A, Nikolic N, Aleksandrovic J, et al. Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone. Lung Cancer. 2003;40:317–323
  14. Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 1992;23:457–467
  15. Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007;68:654–661
  16. Bonner JA, Sloan JA, Shanahan TG, Brooks BT, Marks RS, Krook JE, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999;17:2681–2691
  17. Bogart JA, Herndon JE, Lyss AP, Watson D, Miller AA, Lee ME, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited stage small cell lung cancer: analysis of CALGB 39808. Int J Radiat Oncol Biol Phys. 2004;59:460–468
  18. Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004;22:4837–4845
  19. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol. 2006;17:543–552

PII: S0169-5002(08)00066-4

doi: 10.1016/j.lungcan.2008.02.006

Lung Cancer
Volume 62, Issue 1 , Pages 92-98 , October 2008

Article Tools

* Image Usage & Resolution